-
1 Comment
Korea United Pharm Inc is currently in a long term uptrend where the price is trading 5.4% above its 200 day moving average.
From a valuation standpoint, the stock is 60.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.4.
Korea United Pharm Inc's total revenue rose by 0.3% to $57B since the same quarter in the previous year.
Its net income has dropped by 56.3% to $3B since the same quarter in the previous year.
Finally, its free cash flow grew by 5.5% to $13B since the same quarter in the previous year.
Based on the above factors, Korea United Pharm Inc gets an overall score of 4/5.
| Exchange | KO |
|---|---|
| CurrencyCode | KRW |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| ISIN | KR7033270000 |
| Market Cap | 283B |
|---|---|
| PE Ratio | None |
| Target Price | 37000 |
| Dividend Yield | 2.3% |
| Beta | 0.78 |
Korea United Pharm Inc. engages in the manufacture and sale of pharmaceutical products in South Korea. It offers products in the areas of respiratory system, musculo-skeletal system, gastro-intestinal tract system, cardiovascular system, anti-cancer, anti-infectives, allergy, immune system, central nervous system, and other diseases, as well OTC drugs. The company also exports its products to approximately 40 countries. Korea United Pharm Inc. was founded in 1987 and is headquartered in Seoul, South Korea.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 033270.KO using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
